Transition of psoriasiform drug eruption to psoriasis de novo evidenced by histopathology

Journal of Dermatology

Volumn 35, Issue 11, 2008, Pages 732-736

  Yamamoto, Mayuko ^a   Ikeda, Mitsunori ^a   Kodama, Hajime ^a   Sano, Shigetoshi ^a  

^a KOCHI UNIVERSITY   (Japan)

Author keywords

Apoptosis; Pravastatin; Psoriasiform drug eruption; Signal transducer and activator of transcription 3 (STAT3)

Indexed keywords

CYCLOSPORIN A; ETRETINATE; GLUCOCORTICOID; PRAVASTATIN; STAT3 PROTEIN;

AGED; ANAMNESIS; APOPTOSIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG ERUPTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; NICK END LABELING; PSORIASIS; SKIN BIOPSY; TREATMENT OUTCOME;

AGED, 80 AND OVER; DRUG ERUPTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRAVASTATIN; PSORIASIS; SKIN;

EID: 57449110962     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2008.00558.x     Document Type: Article

References (15)

1. Abel EA. Diagnosis of drug-induced psoriasis. Semin Dermatol 1992 11 : 269 274.
2. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol 2000 1 : 159 165.
3. Tsankov N, Kazandjieva J, Drenovska K. Drugs in exacerbation and provocation of psoriasis. Clin Dermatol 1998 16 : 333 351.
4. Kanerva L. Electron microscopy of the effects of dithranol on healthy and on psoriatic skin. Am J Dermatopathol 1990 12 : 51 62.
5. Sano S, Chan KS, Carbajal S et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005 11 : 43 49.
6. Wrone-Smith T, Johnson T, Nelson B et al. Discordant expression of Bcl-x and Bcl-2 by keratinocytes in vitro and psoriatic keratinocytes in vivo. Am J Pathol 1995 146 : 1079 1088.
7. Wrone-Smith T, Mitra RS, Thompson CB et al. Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am J Pathol 1997 151 : 1321 1329.
8. Umeda J, Sano S, Kogawa K et al. In vivo cooperation between Bcl-xL and the phosphoinositide 3-kinase-Akt signaling pathway for the protection of epidermal keratinocytes from apoptosis. Faseb J 2003 17 : 610 620.
9. Sano S, Chan KS, Digiovanni J. Impact of Stat3 activation upon skin biology: A dichotomy of its role between homeostasis and diseases. J Dermatol Sci 2007 50 : 1 14.
10. Stur K, Karlhofer FM, Stingl G. Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas. J Invest Dermatol 2007 127 : 802 807.
11. Abe R, Shimizu T, Shibaki A et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003 162 : 1515 1520.
12. van Beelen AJ, Teunissen MB, Kapsenberg ML et al. Interleukin-17 in inflammatory skin disorders. Curr Opin Allergy Clin Immunol 2007 7 : 374 381.
13. Zheng Y, Danilenko DM, Valdez P et al. Interleukin -22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007 445 : 648 651.
14. Ma HL, Liang S, Li J et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008 118 : 597 607.
15. Kwak B, Mulhaupt F, Myit S et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000 6 : 1399 1402.